The objective of this study is to obtain viable MSCs from umbilical cords in uncomplicated pregnancies. Potential donors will be screened prior to donation of umbilical cords to confirm no prevalent autoimmune disease. The overall goal is to obtain MSCs from healthy donors for eventual transfusion into patients for the treatment of autoimmune disease, specifically systemic lupus erythematosus.
The goal of this study is to improve racial equality for all pregnant women and their developing babies. We will study women of diverse racial/ethnic backgrounds who will receive either the current vitamin D standard of 400 IU/day (in the prenatal vitamin) or 4400 IU/day (dose found in previous study to achieve vitamin D sufficiency and optimal 1,25(OH)2D production).
The primary purpose of the this study is to evaluate the quality of life of lactating mothers using an all-natural, organic, herbal tea that is currently on the market and has been commercially available for over thirty years in the United States. Compensation is available. Please call the study coordinator for more details.
Epidural block is the gold standard for labor analgesia. However, the onset of optimal analgesia can take 15-20 minutes. This is because the epidural medication has to cross the duramater to block the pain fibres. Puncturing the duramater and deposting of drugs directly in the cerebrospinal fluid results in a quicker onset of action, but is associated with maternal and fetal sideffects. The current study will make a dural puncture but will not deposit the medication in the cerebrospinal fluid. Instead after the dural puncture, the medication will be placed in the epidural space. However, the theoretical dural puncture will facilitate a quicker onset of action without the maternal and fetal side-effects
The human gut hosts trillions of microbes, more than any other ecosystem, making this an important reservoir for microbial mercury cycling. Genes associated with both inorganic mercury methylation and methylmercury demethylation were isolated from human feces, indicating the importance of both processes during digestion and elimination. Our primary hypothesis is that differences in the taxonomic abundance and diversity of maternal gut microbiota impact prenatal methylmercury exposure via at least two possible mechanisms: 1) alteration of the metabolic potency of gut microbes to detoxify methylmercury and enhance its fecal excretion, and/or 2) alteration of the enterohepatic cycling of methylmercury through changes in intestinal permeability and resultant uptake of methylmercury into systemic circulation, potentially impacting the central nervous system and distribution to tissues.
We will test this hypothesis within a cohort of 130 pregnant women and their offspring, who will be recruited at the at the Medical University of South Carolina, located in the coastal city of Charleston, South Carolina. This longitudinal study will establish the relationship between gut ecology and prenatal methylmercury exposure at four time points, targeting prenatal and postnatal periods when shifts in gut microbiota will likely occur, including trimesters 1 (or 2) and 3, delivery, and 18 months postpartum. Through a combination of biomarker assessment (hair, blood, meconium, stools, and urine) and gene profiling of maternal and infant stool samples, the proposed research will advance our understanding of methylmercury metabolism, including impacts to prenatal methylmercury exposure.
The purpose of this study is to determine if exposure to certain chemicals by the mother affects the size of your baby’s genitals.
At the time of enrollment, a maternal urine sample will be collected and tested for bisphenol A and phthalate metabolites, organic compounds that can be found in your urine. This urine sample will be about 80 ml or 5 tablespoons. A blood sample will also be collected at enrollment. This blood sample will be about 30 ml or 2 tablespoons. There is very important information that can be gained by collecting your blood sample and you contribution to this study would be greatly appreciated. However, if you choose not to supply a blood sample, you can still participate in the other portions of the study. If you do not want to participate in the blood collection portion of the study, please notify the study staff. You will also be asked to complete a questionnaire that will allow Dr. Unal and the research staff to have a better idea of your everyday life and your contact with plastic. The questionnaire will be given to you by the study staff at the time of enrollment in the study.
Regardless of where you plan to deliver your baby, if it is determined that you are having a boy during your fetal anatomic ultrasound, we will measure the length and width of your baby's penis. The measurements will be taken using the high resolution picture created by the ultrasound. If it is determined that you are having a girl no measurements will be taken during the ultrasound.
During your scheduled office vist between 24 and 32 weeks gestation, you will be asked to provide a 2nd urine sample. This urine sample will be about 80 ml or 5 tablespoons.
If you plan to deliver at MUSC, then the following procedures will take place after delivery:
At the time of delivery appproximately 15 ml or 1 tablespoon of fetal cord blood will be collected; this does not involve a needle-stick to the baby as the blood is collected directly from the umbilical cord after the placenta is delivered. In addition, approximately 30 ml or 2 tablespoons (two extra tubes of blood) will be collected at the time of IV placement. This blood sample will not involve a needle-stick. Also at the time of delivery an additional maternal urine sample (about 80 ml or 5 tablespoons) will be taken. These samples will be stored for later analysis of bisphenol A, phthalate metabolites, and androgens, which are male hormones.
Genital measurements will also be taken of your baby.
The purpose of this study is to determine whether ‘less tight’ control (aiming for a diastolic blood pressure of 100 mmHg), compared with ‘tight’ control (aiming for a diastolic blood pressure of 85 mmHg), can decrease the risks of adverse (unwanted) baby outcomes without increasing the risk of problems for the mother. The diastolic blood pressure is the bottom number of the blood pressure reading, and is less influenced by what is going on around a woman.
With current standard of care practice, Implanon, a long acting reversible contraceptive measure is placed at the 6 week post partum visit. This study is examining whether or not it is more beneficial to have the Implanon placed prior to leaving the hospital. If you are between 15-21 years of age and are considering using Implanon as your post partum birth control, then you may be eligible to qualify. Study participants have a 50% chance of having Implanon placed prior to leaving the hospital and must commit to completing a baseline questionnaire at enrollment and three follow-up questionnaires by phone at 3,6, and 12 months after delivery. Compensation is available. Please contact the coordinator for more details.